TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Carisma Therapeutics ( (CARM) ).
On August 29, 2025, Carisma Therapeutics Inc. announced a significant merger agreement with OrthoCellix, a subsidiary of Ocugen, Inc. This merger will see OrthoCellix become a wholly-owned subsidiary of Carisma, with plans for a concurrent investment of at least $25 million, including a $5 million investment from Ocugen. The merger aims to strengthen Carisma’s market position and expand its operational capabilities. Additionally, Carisma has amended its employment agreement with CEO Steven Kelly, ensuring leadership continuity post-merger. The merger and investment are subject to customary closing conditions and shareholder approval.
The most recent analyst rating on (CARM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.
Spark’s Take on CARM Stock
According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.
Carisma Therapeutics faces severe financial difficulties, with negative equity and ongoing losses. Technical indicators suggest a bearish outlook, while valuation metrics reflect the company’s struggling position. The recent corporate event highlights compliance issues but also shows attempts to address these challenges.
To see Spark’s full report on CARM stock, click here.
More about Carisma Therapeutics
Carisma Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing innovative therapies. The company is involved in creating advanced treatment options, with a market focus on enhancing healthcare outcomes.
Average Trading Volume: 14,005,843
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.53M
See more insights into CARM stock on TipRanks’ Stock Analysis page.